Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts hold a “Moderate Buy” consensus on Sensus Healthcare, with four buy ratings, one hold and one sell among six analysts. The average 12-month price target is $5.83, although Lake Street Capital recently lowered its target to $4.00.
• Institutional ownership stands at 25.3%, with several funds initiating positions and State Street increasing its stake by 5.2%.
• Sensus Healthcare reported a weak quarter, posting an adjusted loss of $0.53 per share versus the expected $0.12 loss and revenue of $2.29 million versus the $4.60 million consensus estimate. Shares opened at $3.34, within a 52-week range of $2.66 to $5.49.

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $5.8333.

Several equities analysts have recently weighed in on the company. Lake Street Capital lowered their price target on Sensus Healthcare from $4.50 to $4.00 and set a "buy" rating on the stock in a report on Friday, August 14th. Weiss Ratings cut Sensus Healthcare from a "sell (d)" rating to a "sell (d-)" rating in a research report on Tuesday, August 18th. Wall Street Zen downgraded Sensus Healthcare from a "sell" rating to a "strong sell" rating in a report on Saturday, May 9th. Citigroup restated a "buy" rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Finally, Alliance Global Partners reaffirmed a "buy" rating on shares of Sensus Healthcare in a research report on Monday, August 17th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. EP Wealth Advisors LLC bought a new position in Sensus Healthcare in the 2nd quarter worth $49,000. XTX Topco Ltd bought a new position in shares of Sensus Healthcare in the fourth quarter worth about $77,000. Jane Street Group LLC purchased a new position in shares of Sensus Healthcare during the 4th quarter valued at about $79,000. Ingalls & Snyder LLC bought a new position in shares of Sensus Healthcare during the 4th quarter valued at approximately $219,000. Finally, State Street Corp grew its stake in shares of Sensus Healthcare by 5.2% during the 4th quarter. State Street Corp now owns 69,252 shares of the company's stock valued at $276,000 after acquiring an additional 3,400 shares during the period. Hedge funds and other institutional investors own 25.30% of the company's stock.

Sensus Healthcare Stock Performance

SRTS opened at $3.34 on Monday. The company's 50-day simple moving average is $2.99 and its two-hundred day simple moving average is $3.57. The stock has a market capitalization of $54.98 million, a P/E ratio of -3.55 and a beta of 1.10. Sensus Healthcare has a 52-week low of $2.66 and a 52-week high of $5.49.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $4.60 million.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source